文献类型：期刊文献

英文题名：Advances in immunotherapy of M2 macrophages and gastrointestinal stromal tumor

作者：Wang, Xiao-Ke[1];Yang, Xin[1];Yao, Tong-Han[1];Tao, Peng-Xian[2];Jia, Guan-Jun[3];Sun, De-Xian[4];Yi, Lin[3];Gu, Yuan-Hui[2]

第一作者：Wang, Xiao-Ke

通信作者：Gu, YH[1]

机构：[1]Gansu Univ Chinese Med, Sch Clin Med 1, Lanzhou 730000, Gansu, Peoples R China;[2]Gansu Prov Hosp, Dept Gen Surg, 204 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China;[3]Gansu Univ Chinese Med, Sch Tradit Chinese & Western Med, Lanzhou 730000, Gansu, Peoples R China;[4]Qinghai Univ, Grad Sch, Xining 810016, Qinghai, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Prov Hosp, Dept Gen Surg, 204 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China.

年份：2024

卷号：16

期号：7

起止页码：2915

外文期刊名：WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY

收录：;Scopus(收录号：2-s2.0-85199775185);WOS:【SCI-EXPANDED(收录号:WOS:001281630600032)】；

基金：Supported by the National Natural Science Foundation of China, No. 82160842; and Clinical Research Project of Research Fund of Gansu Provincial Hospital, No. 23GSSYD-17.

语种：英文

外文关键词：Gastrointestinal stromal tumor; M2 macrophage; Inflammatory response; Programmed death receptor-1; Programmed death ligand-1; Imatinib; Immunotherapy; Targeted therapy

摘要：Gastrointestinal stromal tumors (GIST) are the most common mesenchymal-derived tumors of the GI tract. They can occur throughout the GI tract, and the survival time of some patients can be improved by first-line targeted therapy with imatinib. However, there are some limitations with imatinib treatment. Immunotherapy for GIST has attracted much attention in recent years, and as one of the most abundant cells in the GIST microenvironment, M2 macrophages play an important role in disease progression. They have unique anti-inflammatory and pro-tumorigenic effects and are one target for immunotherapy. This review summarizes the connection between different factors and the programmed death receptor-1/programmed death ligand-1 pathway and M2 macrophages to reactivate or enhance anti-tumor immunity and improve imatinib efficacy, and to provide new ideas for GIST immunotherapy.